Recombinant human BRD3 (Bromodomain containing 3) BD2 domain, , encompassing amino acids 305-417. This construct contains an N-terminal GST-tag. This protein was affinity purified.
40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, and 3 mM DTT
MW
40 kDa
Amino Acids
306-417
Genbank #
NM_007371
UniProt #
Q15059
Tag(s)
N-terminal GST-tag
Background
BRD3, also known as RING3L (RING3-like protein) belongs to the BET family of proteins and is involved in transcription by associating with acetylated lysine residues present in histones and transcription factors. Chromosomal translocations of BRD3 with NUT (nuclear protein in testis) can lead to cancer, and it has been shown that the use of BET inhibitors or depletion of BRD3 can slow down cancer progression in models of prostate cancer. The use of PROTAC technology for degradation of BRD proteins is an active field of research which maybe prove crucial in cancer therapy.
References
1. Gamsjaeger, R., et al., Mol Cell Biol. 2011 Jul; 31(13): 2632-2640. 2. Lamonica, JM, et al., Proc Natl Acad Sci USA. 2011 May 31; 108(22): E159-168.
Storage/Stability
At least 6 months at –80°C.
Assay Conditions
Assay run according to BRD3 (BD2) Inhibitor Screening Assay Kit (#32523). 100 nM BET Ligand was incubated with various amounts of BRD3 (BD2) for 30 minutes. GSH acceptor bead and streptavidin-conjugated donor beads were added, and the reaction was incubated for 30 minutes. Alpha-counts were measured.
Instructions for Use
Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Applications
Useful for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.